Research Article
Pretreatment 18F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal Cancer
Table 1
Patient and tumor characteristics.
| | Characteristics | Cases (%) |
| | Patients, n | 85 |
| | Gender | | | Male | 51 (60%) | | Female | 34 (40%) |
| | Age, years | | | Mean ± SD | 59.27 ± 11.56 | | Range | 26–79 |
| | BMI | | | Mean ± SD | 21.97 ± 3.21 | | Range | 15.43–33.87 |
| | Tumor location | | | Left hemicolon | 33 (38.9%) | | Right hemicolon | 22 (25.9%) | | Rectum | 30 (35.2%) |
| | Histologic type | | | Nonmucinous adenocarcinoma | 83 (97.6%) | | Mucinous adenocarcinoma | 2 (2.4%) |
| | Differentiation | | | Well/moderate | 74 (87.1%) | | Poor | 11 (12.9%) |
| | UICC-TNM stage | | | I/II | 33 (38.8%) | | III/IV | 52 (61.2%) |
| | T-category | | | Tis, T1, T2 | 4 (4.7%) | | T3, T4 | 81 (95.3%) |
| | N-category | | | Positive | 67 (78.8%) | | Negative | 18 (21.2%) |
| | M-category | | | Positive | 56 (65.9%) | | Negative | 29 (34.1%) |
| | Tumor size, mm | | | Mean ± SD | 49.2 ± 28.17 | | Range | 10–180 |
| | Mutational status | | | KRAS/NRAS/BRAF mutated | 46 (54.1%) | | Wild-type | 39 (45.9%) |
|
|
UICC, Union for International Cancer Control.
|
